Membranous lupus nephritis secondary to secukinumab therapy : A case report and literature review
The interleukin (IL)-17 axis is involved in many inflammatory and autoimmune diseases. Secukinumab, an IL-17 inhibitor, has been approved for psoriasis treatment. There are accumulating cases of lupus erythematosus induced by IL-17 inhibition. Lupus nephritis after IL-17 inhibition has not been reported. We report the case of a 57-year-old man who developed membranous lupus nephritis after secukinumab treatment for psoriasis. Anti-SSA and PM-Scl antibodies were positive. dsDNA, anti-Smith, and anti-histone antibodies were negative, and serum complement was low. Secukinumab was discontinued, while tacrolimus was initiated, subsequently switched to cyclosporin, belimumab, glucocorticosteroid, and hydroxychloroquine with a good response. The relationship between lupus erythematosus and IL-17 inhibition requires further research.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
---|---|
Enthalten in: |
Lupus - 33(2024), 6 vom: 01. Apr., Seite 644-649 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Zhou, Yi [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antibodies, Monoclonal, Humanized |
---|
Anmerkungen: |
Date Completed 15.04.2024 Date Revised 15.04.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1177/09612033241242698 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM370590902 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM370590902 | ||
003 | DE-627 | ||
005 | 20240415233646.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240404s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1177/09612033241242698 |2 doi | |
028 | 5 | 2 | |a pubmed24n1376.xml |
035 | |a (DE-627)NLM370590902 | ||
035 | |a (NLM)38569663 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Zhou, Yi |e verfasserin |4 aut | |
245 | 1 | 0 | |a Membranous lupus nephritis secondary to secukinumab therapy |b A case report and literature review |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 15.04.2024 | ||
500 | |a Date Revised 15.04.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a The interleukin (IL)-17 axis is involved in many inflammatory and autoimmune diseases. Secukinumab, an IL-17 inhibitor, has been approved for psoriasis treatment. There are accumulating cases of lupus erythematosus induced by IL-17 inhibition. Lupus nephritis after IL-17 inhibition has not been reported. We report the case of a 57-year-old man who developed membranous lupus nephritis after secukinumab treatment for psoriasis. Anti-SSA and PM-Scl antibodies were positive. dsDNA, anti-Smith, and anti-histone antibodies were negative, and serum complement was low. Secukinumab was discontinued, while tacrolimus was initiated, subsequently switched to cyclosporin, belimumab, glucocorticosteroid, and hydroxychloroquine with a good response. The relationship between lupus erythematosus and IL-17 inhibition requires further research | ||
650 | 4 | |a Review | |
650 | 4 | |a Case Reports | |
650 | 4 | |a Journal Article | |
650 | 4 | |a IL-17 inhibitors | |
650 | 4 | |a Membranous lupus nephritis | |
650 | 4 | |a biopsy | |
650 | 4 | |a drug-induced lupus erythematosus | |
650 | 4 | |a pathology | |
650 | 4 | |a secukinumab | |
650 | 7 | |a secukinumab |2 NLM | |
650 | 7 | |a DLG4EML025 |2 NLM | |
650 | 7 | |a Interleukin-17 |2 NLM | |
650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
700 | 1 | |a Hu, Zhangxue |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Lupus |d 1991 |g 33(2024), 6 vom: 01. Apr., Seite 644-649 |w (DE-627)NLM012651214 |x 1477-0962 |7 nnns |
773 | 1 | 8 | |g volume:33 |g year:2024 |g number:6 |g day:01 |g month:04 |g pages:644-649 |
856 | 4 | 0 | |u http://dx.doi.org/10.1177/09612033241242698 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 33 |j 2024 |e 6 |b 01 |c 04 |h 644-649 |